Therefore, we suggest that the 2022 ACR/EULAR criteria for AAV should be applied to PM/DM patients who had MPO-ANCA (or P-ANCA) or PR3-ANCA (or C-ANCA) along with any evidence of small- and medium-vessel vasculitis. This evidence concerns the gene PRTN3 and dermatomyositis.